{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:14:48Z","timestamp":1790882088608,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["SBGJ202302078"],"award-info":[{"award-number":["SBGJ202302078"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.heliyon.2025.e42729","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:20:29Z","timestamp":1739640029000},"page":"e42729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy"],"prefix":"10.1016","volume":"11","author":[{"given":"Fei-fan","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-qin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-1924","authenticated-orcid":false,"given":"Jian-jiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.heliyon.2025.e42729_bib1","first-page":"694","article-title":"Les ddp\u00f4ts intercapillaires d'IgA-IgG [Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey","volume":"33","author":"O'Shaughnessy","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"19","key":"10.1016\/j.heliyon.2025.e42729_bib3","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42729_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e42729_bib5","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2005020134","article-title":"IgA nephropathy","volume":"16","author":"Barratt","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42729_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42729_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2025.e42729_bib8","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin. Kidney J."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42729_bib9","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42729_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.trsl.2015.02.007","article-title":"Immunoglobulin A nephropathy: current progress and future directions","volume":"166","author":"Zhang","year":"2015","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.heliyon.2025.e42729_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42729_bib14","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"23","key":"10.1016\/j.heliyon.2025.e42729_bib16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42729_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"10405","key":"10.1016\/j.heliyon.2025.e42729_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2025.e42729_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: an interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2025.e42729_bib20","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00467-017-3628-1","article-title":"Inflammation in IgA nephropathy","volume":"32","author":"Rauen","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"109","author":"Kiryluk","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2025.e42729_bib22","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/ndt\/gfad125","article-title":"Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy","volume":"28","author":"Peters","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42729_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00281-021-00878-5","article-title":"Are there animal models of IgA nephropathy?","volume":"43","author":"Monteiro","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42729_bib25","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3390\/biomedicines10123027","article-title":"Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy","volume":"10","author":"Kano","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-01741-9","article-title":"Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study","volume":"21","author":"Hu","year":"2020","journal-title":"BMC Nephrol."},{"issue":"25","key":"10.1016\/j.heliyon.2025.e42729_bib29","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42729_bib30","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1681\/ASN.2006060658","article-title":"O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy","volume":"17","author":"Smith","year":"2006","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42729_bib31","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.heliyon.2025.e42729_bib32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 b cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors","volume":"33","author":"Zachova","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0022-4731(82)90035-8","article-title":"Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids","volume":"16","author":"Brattsand","year":"1982","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.heliyon.2025.e42729_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425247.2.1.159","article-title":"TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract","volume":"2","author":"Watts","year":"2005","journal-title":"Expet Opin. Drug Deliv."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42729_bib34","doi-asserted-by":"crossref","DOI":"10.2217\/frd-2021-0013","article-title":"Nefecon (targeted-release formulation-budesonide) for the treatment of IgA nephropathy","volume":"1","author":"Vecchio","year":"2021","journal-title":"Future Rare Dis."},{"key":"10.1016\/j.heliyon.2025.e42729_bib35","article-title":"Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: a comprehensive review","volume":"13","author":"Liao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.ajkd.2021.12.011","article-title":"Principles of immunosuppression in the management of kidney disease: core curriculum 2022","volume":"80","author":"Kant","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.heliyon.2025.e42729_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eci.11.34","article-title":"Budesonide in the treatment of inflammatory bowel disease","volume":"7","author":"Silverman","year":"2011","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib40","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.heliyon.2025.e42729_bib41","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2025.e42729_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA nephropathy","volume":"99","author":"Ismail","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42729_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47393-1","article-title":"An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression","volume":"13","author":"Obri\u0219c\u0103","year":"2023","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42729_bib55","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.34067\/KID.0000000583","article-title":"Efficacy and safety of Nefecon in patients with IgA nephropathy from Mainland China: 2-year NefIgArd trial results","volume":"5","author":"Zhang","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.heliyon.2025.e42729_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/jpc.14259","article-title":"Childhood IgA nephropathy successfully treated with targeted\u2010release budesonide: a case report","volume":"54","author":"Venettacci","year":"2018","journal-title":"J. Paediatr. Child Health"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42729_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4103\/1319-2442.284029","article-title":"Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide","volume":"31","author":"Lingaraj","year":"2020","journal-title":"Saudi J. Kidney Dis. Transplant."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e42729_bib45","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s00467-022-05630-1","article-title":"Abstracts of the 54th ESPN annual meeting, Ljubljana, Slovenia","volume":"37","year":"2022","journal-title":"Pediatr. Nephrol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42729_bib46","first-page":"849","article-title":"A pediatric case of IgA nephropathy benefitting from targeted release formulation\u2013budesonide","volume":"38","author":"Antonucci","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.heliyon.2025.e42729_bib48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/oxfordjournals.qjmed.a068052","article-title":"Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases","volume":"61","author":"Kobayashi","year":"1986","journal-title":"QJM: Int. J. Med."},{"key":"10.1016\/j.heliyon.2025.e42729_bib49","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2025.e42729_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-024-02071-x","article-title":"Italian Group of Steroids in IgAN. The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort","author":"Baragetti","year":"2024","journal-title":"J. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42729_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42729_bib51","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.heliyon.2025.e42729_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42729_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int. Rep."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42729_bib54","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of Nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int. Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025011107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025011107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:34:17Z","timestamp":1784068457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025011107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2405844025011107"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42729","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e42729"}}